Group 1 - On January 19, several companies disclosed share buyback and increase plans, including Hongya CNC, Tianyi Medical, and Aotai Bio [1][4] - Hongya CNC's controlling shareholder plans to increase company shares by 30 million to 60 million yuan [3][6] - Tianyi Medical has received a commitment letter for a 90 million yuan stock repurchase loan from Quanrong Institution [3][6] - Aotai Bio's controlling shareholder and chairman proposed a share repurchase [3][6] Group 2 - A total of 11 A-share listed companies disclosed share reduction plans, including Huning Co., Yiwan Yichuang, and Zhaobiao Co. [1][4] - Huning Co. shareholders plan to reduce their holdings by no more than 1.1972% [7] - Yiwan Yichuang's shareholder Zhang Fan reduced holdings by 2.319427 million shares on January 16 [7] - Zhaobiao Co. shareholders plan to reduce holdings by no more than 0.06% [7] - Meihua Medical shareholders plan to reduce holdings by no more than 2.51% [7] - Wuhan Tianyuan shareholders, including Konka Group and Hongta Innovation, plan to reduce holdings by no more than 2% [7] - Jianglong Shipbuilding's director plans to reduce holdings by no more than 0.6423% [7] - Changying Precision's controlling shareholder plans to reduce holdings by no more than 1% [7] - Hanke Technology's actual controller and concerted actors plan to reduce holdings by no more than 0.43% [7] - Kangqiang Electronics plans to reduce 1.9528 million shares from December 8, 2025, to January 19, 2026 [7] - Top Software's shareholder Aipai Ke plans to reduce holdings by no more than 0.87% [7] - Western Gold's controlling shareholder plans to reduce holdings by no more than 1% [7]

Core Viewpoint - Tianyi Medical (301097.SZ) has obtained a loan commitment letter from the Ningbo branch of the Industrial and Commercial Bank of China, indicating a strategic move to repurchase its own shares [1] Group 1: Loan Details - Loan Amount: Up to 90 million RMB [1] - Loan Term: Not exceeding 3 years [1] - Loan Purpose: Specifically for the repurchase of the company's stock [1]

Core Viewpoint - Tianyi Medical (301097.SZ) has obtained a loan commitment letter from the Ningbo branch of the Industrial and Commercial Bank of China, indicating a strategic move to repurchase its own shares [1] Group 1: Loan Details - Loan Amount: Up to 90 million RMB [1] - Loan Term: Not exceeding 3 years [1] - Loan Purpose: Specifically for the repurchase of the company's stock [1]

Core Viewpoint - Tianyi Medical has received a medical device registration certificate from the National Medical Products Administration for its product, a disposable continuous renal replacement therapy circuit, valid until January 13, 2031 [2]. Group 1 - The product name is "disposable continuous renal replacement therapy circuit" [2]. - The registration certificate number is 20263100049 [2]. - The effective period of the registration certificate is until January 13, 2031 [2].

证券代码：301097 证券简称：天益医疗 公告编号：2026-007 宁波天益医疗器械股份有限公司 关于取得金融机构股票回购专项贷款承诺函的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 宁波天益医疗器械股份有限公司（以下简称"公司"）于 2026 年 1 月 12 日召开第四届董事会第二次会议，审议通过了《关于回购公司股份方案的议案》， 同意公司使用自有资金或银行贷款以集中竞价方式回购公司股份，在未来择机用 于实施股权激励或员工持股计划，回购的资金总额不低于人民币 6,000 万元(含) 且不超过人民币 12,000 万元(含)，回购价格不超过人民币 65 元/股，回购股份 的实施期限自公司董事会审议通过本次回购股份方案之日起 12 个月内。具体内 容详见公司于 2026 年 1 月 12 日在中国证监会指定创业板信息披露网站巨潮资讯 网上发布的相关公告。 一、回购公司股份方案的基本情况 公司本次回购符合《上市公司股份回购规则》第八条规定的条件： 二、取得金融机构股票回购专项贷款承诺函的情况 近日，公司取得了中国工商银行股份有限公司宁波市分行出具的《 ...

Core Viewpoint - Tianyi Medical (301097.SZ) has received a medical device registration certificate from the National Medical Products Administration for its product, a disposable continuous renal replacement therapy circuit [1] Group 1: Product Details - The registered product is a complete and integrated system designed for extracorporeal circulation, specifically for continuous renal replacement therapy [1] - The multi-channel design and comprehensive safety accessories of the product are tailored to meet the clinical operational and safety needs in intensive care environments [1] - The product is compatible with the Nikkiso Aquarius blood purification device [1] Group 2: Market Implications - The issuance of the registration certificate signifies the successful extension of the company's product registration, demonstrating ongoing compliance with regulatory requirements [1] - This development is expected to positively impact the company's market competitiveness and expansion [1]

Core Viewpoint - Tianyi Medical has received a medical device registration certificate from the National Medical Products Administration for a single-use continuous renal replacement therapy circuit, indicating a significant advancement in its product offerings in the renal therapy market [1] Group 1: Product Details - The newly certified product is designed to be used with the AQUARIUS series of continuous blood purification devices and specialized filters for continuous renal replacement therapy [1] - It supports various treatment modalities including slow continuous ultrafiltration (SCUF), continuous venovenous hemofiltration (CVVH), continuous venovenous hemodialysis (CVVHD), continuous venovenous hemodialysis with filtration (CVVHDF), therapeutic plasma exchange (TPE), and blood perfusion (HP) [1] - The product is responsible for the function of blood and fluid pathways, enhancing the efficiency and effectiveness of renal replacement therapies [1]

Core Viewpoint - Tianyi Medical (301097.SZ) has received a medical device registration certificate from the National Medical Products Administration for its disposable continuous renal replacement therapy circuit, indicating compliance with regulatory requirements and enhancing market competitiveness [1] Group 1: Product Details - The registered product is a complete, integrated, and reliable extracorporeal circulation circuit system designed for continuous renal replacement therapy in critical care settings [1] - The system features a highly integrated multi-tube design and comprehensive safety accessories to meet clinical operational and safety needs [1] - It is compatible with the Nikkiso Aquarius blood purification device, indicating its applicability in advanced medical settings [1] Group 2: Market Implications - The issuance of the registration certificate signifies a successful extension of the company's product registration, reinforcing its commitment to regulatory compliance [1] - This development is expected to positively impact the company's market competitiveness and ability to expand its market presence [1]

二、对公司的影响 公司本次获得医疗器械注册证的一次性使用连续性肾脏替代治疗管路由动 脉管、静脉管、置换液管、废液管、预充针、预充袋、废液袋、透析器连接管、 侧口浓缩接头连接管、附件管组成，由动静脉接头保护套、动静脉接头、主导管、 T 型三通、测压器、泵管接头（二通或三通）、泵管、采样口（三通或四通）、 大止流夹、外圆锥接头、锁口接头、锁口接头保护套、导管、小止流夹、带翼内 圆锥接头、密封式保护套、肝素管、单向阀、滴斗、预充针、穿刺器保护套、气 体捕获器、过滤网、鲁尔接头、测压管、传感器保护器、加热管、L 型接头、U 型三通接头、废液袋、预充袋、转换接头保护帽、带盖浓缩侧孔接头组成。产品 一次性使用，环氧乙烷灭菌。 证券代码： 301097 证券简称：天益医疗 公告编号：2026-006 宁波天益医疗器械股份有限公司 关于公司新产品取得产品注册证书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 宁波天益医疗器械股份有限公司（以下简称"公司"）于近日收到国家药品 监督管理局颁发的《医疗器械注册证》，具体情况如下： | 序号 | 产品名称 | 注册证编号 | ...

Group 1 - Tianyi Medical experienced a decline of 5.06% on January 15, with a stock price of 54.42 yuan per share, a trading volume of 54.43 million yuan, a turnover rate of 3.40%, and a total market capitalization of 3.208 billion yuan [1] - Ningbo Tianyi Medical Equipment Co., Ltd. was established on March 12, 1998, and went public on April 7, 2022. The company specializes in the research, production, and sales of medical devices related to blood purification and ward care, with revenue composition of 59.05% from blood purification, 34.08% from ward care, and 6.87% from other sources [1] Group 2 - CITIC Prudential Fund's multi-strategy mixed fund (LOF) A (165531) entered the top ten circulating shareholders of Tianyi Medical in the third quarter, holding 207,900 shares, which is 1.13% of the circulating shares. The estimated floating loss today is approximately 602,900 yuan [2] - The CITIC Prudential multi-strategy mixed fund (LOF) A (165531) was established on June 16, 2017, with a latest scale of 1.133 billion yuan. Year-to-date returns are 5.2%, ranking 3139 out of 8840 in its category; the one-year return is 51.86%, ranking 1828 out of 8094; and since inception, the return is 159.16% [2]